Luis Jara-Palomares Spain

Dr. Jara-Palomares’s research activity in this field has resulted in 197 publications, with 3,635 citations, and 33.9% of his works ranked among the top 25% most cited worldwide. A total of 58.4% of manuscripts were published in first-quartile journals according to CiteScore percentiles. His publications have had a significant impact across 22 categories (Scopus), with the most relevant being: 1. Venous Thromboembolism; Cancer; Anticoagulant Agents: 26 documents. 2. Pulmonary Embolism; Embolectomy. 3. Blood Clot Lysis: 12 documents; Pulmonary Embolism; Fibrin Fragment D; Vein Thrombosis: 7 documents. He has co-authored several international guidelines and consensus statements: • ESMO Guidelines on cancer-associated VTE (Annals of Oncology 2023; PMID: 36638869). • Multidisciplinary Consensus on Pulmonary Embolism (Arch Bronconeumol 2021). • Consensus on Optimal Management of Pulmonary Embolism (Eur Heart J 2022; PMID: 34875048). • Panelist in iTAC Guidelines on cancer-associated VTE (Lancet Oncology 2019 and 2022; PMID: 31492632 and 35772465). His H-index is 33 (Web of Science). Supervised PhD Theses and Master’s Dissertations (last 5 years) 1. Dr. Samira Marín Romero – PhD, Universidad de Sevilla (2020). Long-term treatment controversies in patients with unprovoked venous thromboembolism and cancer-associated thrombosis. Grade: Summa Cum Laude. Thesis by com-pendium of articles. 2. Dr. Sergio López Ruz – PhD, Universidad de Sevilla (2023). Therapeutic ma-nagement controversies in venous thromboembolism in complex patients. Grade: Outstanding. Thesis by compendium of articles. 3. Dr. María Barca Hernando – PhD, Universidad de Sevilla (2024). Venous thromboembolism in cancer patients: therapeutic management and complica-tions. Grade: Summa Cum Laude. Thesis by compendium of articles. 4. Dr. Aurora Solier López – PhD, Universidad de Sevilla (2024). Duration of an-ticoagulant treatment in cancer-associated venous thromboembolism. Grade: Summa Cum Laude. 5. Dr. Lucía Marín Barrera – PhD, Universidad de Sevilla (2025). Health-related quality of life in cancer patients with acute symptomatic venous thromboembo-lism. A case-control study. Grade: Summa Cum Laude. PhD theses pending defense in 2025: Víctor García García, Carmen Rosa Linares. Master’s Teaching Activities • Master in Clinical Research Methodology in Pulmonary Embolism (3 edi-tions). • Master in VTE, University of Navarra (2021–22 and 2023–24). • Vascular Master’s, CEU San Pablo University (2023–24). Human Resources Supervision • Rio Hortega Fellowship (ISCIII): CM20/00162 – Beneficiary: Samira Marín Romero. PI: Luis Jara Palomares. Center: Hospital Universitario Virgen del Rocío / IBIS (2021–2023). • Rio Hortega Fellowship (ISCIII): CM22/00234 – Beneficiary: María Barca Hernando. PI: Luis Jara Palomares. Center: Hospital Universitario Virgen del Ro-cío / IBIS (2023–2024). • Research Intensification Grant – ISCIII (2023–2024). • Junior Specialist Postdoctoral Contract, Andalusian Health Ministry: RHE-0028-2024. Beneficiary: María Barca Hernando. Teaching of Health Sciences Trainees (FSE) • Clinical tutor (PI, co-PI) of 4th- and 6th-year medical students, Universidad de Sevilla. • Clinical tutor (PI, co-PI) of internal medicine, vascular medicine, and pulmonolo-gy residents rotating in the Venous Thromboembolism Unit at Hospital Universi-tario Virgen del Rocío. Head of the Unit From October 2025
Job Title
Pulmonologist
Faculty / Department / Division
Head of Pulmonology Unit. Director of Medical-Surgical Unit
Institution / Organisation
Hospital Universitario Virgen del Rocio

21 November 2026, Saturday

Time Session
11:00
12:30
Chai Chan Sin Chairperson Malaysia
Fatimah Azmah Mohammad Chairperson Malaysia
  • Parth Rali Speaker United States
  • Luis Jara-Palomares Speaker Spain
    Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially treatable cause of pulmonary hypertension characterised by persistent organised pulmonary arterial obstruction and secondary microvascular remodelling. Despite advances in management, delayed recognition and unequal access to expert care remain important challenges. This presentation reviews the contemporary diagnostic and therapeutic pathway, integrating guideline recommendations with evidence from clinical trials and international registries. Persistent dyspnoea or exercise limitation after pulmonary embolism should prompt structured assessment, while the absence of a recognised embolic event does not exclude CTEPH. Ventilation–perfusion imaging, anatomical assessment and right heart catheterisation provide complementary information for diagnosis and treatment planning. Multidisciplinary evaluation is central to selecting pulmonary endarterectomy, balloon pulmonary angioplasty and medical therapy. Lifelong therapeutic anticoagulation remains essential, although uncertainty persists regarding the optimal anticoagulant for patients without antiphospholipid syndrome. Symptomatic chronic thromboembolic pulmonary disease without resting pulmonary hypertension requires careful symptom attribution and individualised treatment decisions. Future developments include circulating biomarkers, novel therapies targeting vascular remodelling and artificial intelligence for earlier detection, complication prediction and phenotyping. Multimodal models integrating clinical, biochemical and imaging data could support diagnostic testing and referral decisions, but require external validation and prospective demonstration of clinical benefit. Earlier recognition, timely expert referral and individualised multimodal care remain the priorities for improving outcomes.
  • Q&A
Ballroom 3, Lower Ground Floor